These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36437379)

  • 21. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.
    Wu SL; Yu X; Mao X; Jin F
    BMC Cancer; 2022 Jul; 22(1):782. PubMed ID: 35843951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic Features and Immune Cell Subtypes Analysis of Tumor-infiltrating Lymphocytes Rich Invasive Breast Carcinoma of No Special Type.
    Zhao Y; Huang T; Jin X; Gong XM; Lu YZ
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):354-362. PubMed ID: 37278279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.
    Kim NI; Park MH; Lee JS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):767-775. PubMed ID: 31714284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer.
    Abd El-Maqsoud NM; Abd El-Rehim DM
    Clin Breast Cancer; 2014 Feb; 14(1):e1-9. PubMed ID: 24201161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
    Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
    Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
    Ubago JM; Blanco LZ; Shen T; Siziopikou KP
    Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
    Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
    Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
    Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential prognostic impact of CD8
    Kwak Y; Koh J; Park Y; Hong YJ; Park KU; Kim HH; Park DJ; Ahn SH; Kim WH; Lee HS
    Br J Cancer; 2020 Apr; 122(9):1399-1408. PubMed ID: 32203213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.